HRT Hormone Replacement Therapy

HRT Hormone Replacement Therapy



Can hormone replacement therapy - HRT - reduce the psychological problems I am experiencing?

Home
Blog - What's New?
Abortion
Acne
Amenorrhoea - Absent Periods
Anatomy Female
Birth Control
Bladder Symptoms
Breast Feeding
Cancer in Women
Childbirth
Diet / Weight Loss
Dysmenorrhoea
Ectopic Pregnancy
Endometrial Ablation
Endometriosis
Female Sexual Problems
Female Sterilization
Fibroids
HRT/HormoneReplacementTherapy
Hysterectomy
Infection
Infertility
Irritable Bowel Syndrome IBS
Libido - Sex Drive
Medication - Drugs
Menopause
Menorrhagia Heavy Periods
Menstruation Menstrual Cycle
Miscarriage
Obesity
Ovarian Cysts
Painful Sex - Dyspareunia
Pap Smear Test
PCOS
Pelvic Inflammatory Disease
Pelvic Pain
PMS- Premenstrual Syndrome
Pregnancy & Childbirth
Prolapse
SHOP / SHOPPING MALL UK
SHOP / Shopping Mall - USA
Ultrasound
Urinary Tract Infection - UTI
Urinary Incontinence
Vaginal Discharge
Viagra, Libido and Sex Drive.
Weight Loss-Dieting
Illustrations
The Author
Contact Us

Arch Gen Psychiatry. 2001 Jun;58(6):529-34.

Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial.

Soares CN, Almeida OP, Joffe H, Cohen LS.

Perinatal and Reproductive Psychiatry Clinical Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman St, WACC 812, Boston, MA 02114, USA. csoares@partners.org

Background:

Results of previous studies suggest that estrogen improves somatic and mild depressive symptoms experienced by perimenopausal women. This study investigated the efficacy of 17beta-estradiol for the treatment of clinically significant depressive disorders in endocrinologically confirmed perimenopausal women.

Methods:

Perimenopausal women (aged 40-55 years, with irregular menstrual periods and serum concentrations of follicle-stimulating hormone >25 IU/L), meeting criteria for major depressive disorder, dysthymic disorder, or minor depressive disorder, according to DSM-IV, were randomized to receive transdermal patches of 17beta-estradiol (100 microgram) or placebo in a 12-week, double-blind, placebo-controlled study. A 4-week washout period followed the 12-week treatment phase. Outcome measures were the Montgomery-Asberg Depression Rating Scale and Blatt-Kupperman Menopausal Index scores.

Results:

Fifty women were enrolled in the study; 26 met DSM-IV criteria for major depressive disorder, 11 for dysthymic disorder, and 13 for minor depressive disorder. Remission of depression was observed in 17 (68%) women treated with 17beta-estradiol compared with 5 (20%) in the placebo group (P =.001). Subjects responded similarly to estradiol treatment, regardless of DSM-IV diagnosis. Patients treated with estradiol sustained antidepressant benefit of treatment after the 4-week washout period, although somatic complaints increased in frequency and intensity. Treatment was well tolerated and adverse events were rare in both groups.

Conclusion:

Transdermal estradiol replacement is an effective treatment of depression for perimenopausal women.



Back Home Up Next

Please click on the required question.